Improvement of Vascular Function by Acute and Chronic Treatment with the GPR30 Agonist G1 in Experimental Diabetes Mellitus
Open Access
- 5 June 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (6), e38787
- https://doi.org/10.1371/journal.pone.0038787
Abstract
The G-protein coupled estrogen receptor 30 (GPR30) is a seven-transmembrane domain receptor that mediates rapid estrogen responses in a wide variety of cell types. This receptor is highly expressed in the cardiovascular system, and exerts vasodilatory effects. The objective of the present study was to investigate the effects of GPR30 on vascular responsiveness in diabetic ovariectomized (OVX) rats and elucidate the possible mechanism involved. The roles of GPR30 were evaluated in the thoracic aorta and cultured endothelial cells. The GPR30 agonist G1 induced a dose-dependent vasodilation in the thoracic aorta of the diabetic OVX rats, which was partially attenuated by the nitric oxide synthase (NOS) inhibitor, nitro-L-arginine methylester (L-NAME) and the GPR30-selective antagonist G15. Dose-dependent vasoconstrictive responses to phenylephrine were attenuated significantly in the rings of the thoracic aorta following the acute G1 administration in the diabetic OVX rats. This effect of G1 was abolished partially by L-NAME and G15. The acute administration of G1 increased significantly the eNOS activity and the concentration of NO in the endothelial cells exposed to high glucose. G1 treatment induced an enhanced endothelium-dependent relaxation to acetylcholine (Ach) in the diabetic OVX rats. Further examination revealed that G1 induced vasodilation in the diabetic OVX rats by increasing the phosphorylation of eNOS. These findings provide preliminary evidence that GPR30 activation leads to eNOS activation, as well as vasodilation, to a certain degree and has beneficial effects on vascular function in diabetic OVX rats.This publication has 36 references indexed in Scilit:
- eNOS, metabolic syndrome and cardiovascular diseaseTrends in Endocrinology & Metabolism, 2009
- In vivo effects of a GPR30 antagonistNature Chemical Biology, 2009
- Regulatory Role of G Protein–Coupled Estrogen Receptor for Vascular Function and ObesityCirculation Research, 2009
- Down-regulation of NR2B receptors partially contributes to analgesic effects of Gentiopicroside in persistent inflammatory painNeuropharmacology, 2008
- GPR30: a novel therapeutic target in estrogen-related diseaseTrends in Pharmacological Sciences, 2008
- Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylationJournal of Molecular and Cellular Cardiology, 2007
- Virtual and biomolecular screening converge on a selective agonist for GPR30Nature Chemical Biology, 2006
- Vascular complications in diabetes mellitus: the role of endothelial dysfunctionClinical Science, 2005
- Haematocrit, type 2 diabetes, and endothelium-dependent vasodilatation of resistance vesselsEuropean Heart Journal, 2005
- Deficient Platelet-Derived Nitric Oxide and Enhanced Hemostasis in Mice Lacking the NOSIII GeneCirculation Research, 1999